Making medicines evergreen

Flynn Pharma’s reply to Brunet

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f358 (Published 22 January 2013)
Cite this as: BMJ 2013;346:f358

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. David Walters, director1
  1. 1Flynn Pharma, Stevenage SG1 3EE, UK
  1. david.walters{at}flynnpharma.com

In response to Brunet,1 2 it is complex and expensive to manage the end of the life cycle of a declining product that is essential for patients. The most important consideration for patients was that the capsules were retained on the market, which would not have been …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL